GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
- 20 June 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (25), 5068-5077
- https://doi.org/10.1182/blood-2012-10-460170
Abstract
Key Points: GM-CSF–dependent STAT5 hypersensitivity is detected in 90% of CMML samples and is enhanced by signaling mutations. Treatment with a GM-CSF–neutralizing antibody and JAK2 inhibitors reveals therapeutic potential.Keywords
This publication has 39 references indexed in Scilit:
- SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Blood, 2012
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcomeBlood, 2012
- Paroxysmal nocturnal hemoglobinuria and concurrent JAK2V617F mutationBlood Cancer Journal, 2012
- Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3APublished by American Society of Hematology ,2011
- A novel tumour-suppressor function for the Notch pathway in myeloid leukaemiaNature, 2011
- Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemiaBlood, 2010
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in diseaseBlood, 2009
- Therapeutic potential of JAK2 inhibitorsHematology-American Society Hematology Education Program, 2009
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic CorrelatesCancer Cell, 2008